Please assess the completion status of the following clinical trial:

Trial Title: Risperidone and Suicidality in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 19-60 years of age~2. Diagnosis of major depressive disorder, currently severe with suicidality~3. A total score of Montgomery-Asberg Depression Rating Scale (MADRS) =/\> 25 with the suicide sub-score =/\> 4~4. Currently is taking an antidepressant at a therapeutic dose for longer than 3 weeks~5. In good physical health~Exclusion Criteria:~1. Depression without suicidality~2. Presence of major psychiatric conditions other than major depressive disorder, such as bipolar disorder, schizophrenia, or anxiety disorders (except for generalized anxiety disorder)~3. Depressive symptoms induced by alcohol or substance abuse~4. Psychotic features which are predominant at the initial evaluation~5. Unstable major medical illness, such as cardiac disease or diabetes~6. Female subjects who are pregnant, breastfeeding, or, if of child-bearing potential, unwilling to use adequate birth control measures

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- risperidone (Type: EXPERIMENTAL): risperidone
- placebo (Type: PLACEBO_COMPARATOR): placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).